What is Neuromark?
Neuromark is a pioneering medical technology firm dedicated to the development of highly innovative, non-surgical interventions for chronic inflammatory sino-nasal diseases. The company's flagship NEUROMARK procedure provides a gentle, minimally invasive solution for chronic rhinitis by targeting overactive nasal nerves. By offering a clinical alternative that mitigates common symptoms such as congestion, rhinorrhea, and sneezing without the intense side effects associated with traditional surgical methods, Neuromark has positioned itself as a leader in patient-centric otolaryngology care. The company's focus on rapid recovery and long-term symptom management addresses a significant unmet need in the global healthcare landscape.
How much funding has Neuromark raised?
Neuromark has raised a total of $113.8M across 1 funding round:
Series C
$74M
Series C (2026): $74M with participation from EQT, Atlantic Bridge, Enterprise Ireland, Sofinnova Partners, and MVM Partners
Key Investors in Neuromark
EQT
EQT Private Capital is a global investment platform that partners with companies across various development stages, applying a thematic approach to healthcare and industrial technology sectors.
Sofinnova Partners
A leading European venture capital firm specializing in life sciences, Sofinnova Partners acts as a hands-on company builder, supporting transformative innovations from seed to later-stage development.
MVM Partners
MVM Partners is a specialized investment firm focused on innovative healthcare companies, providing capital and strategic guidance to drive growth in medical technology and digital health.
What's next for Neuromark?
With this major enterprise-level funding, Neuromark is well-positioned to accelerate its commercial expansion and deepen its clinical research initiatives. The strategic capital will likely be deployed to scale manufacturing capabilities, broaden market access across international territories, and support ongoing clinical trials to further validate the efficacy of the NEUROMARK procedure. As the company transitions into this next phase of growth, it remains focused on establishing new standards of care in the medical device sector, leveraging its unique technological edge to capture a larger share of the addressable market for chronic respiratory conditions.
See full Neuromark company page
